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of Commercial Genomic Profiles Used to Assess
Health Risks and Personalize Health Interventions
A. Cecile J.W. Janssens,1,* Marta Gwinn,2 Linda A. Bradley,2 Ben A. Oostra,3 Cornelia M. van Duijn,4
and Muin J. Khoury2
Predictive genomic proﬁling used to produce personalized nutrition and other lifestyle health recommendations is currently offered
directly to consumers. By examining previous meta-analyses and HuGE reviews, we assessed the scientiﬁc evidence supporting the pur-
ported gene-disease associations for genes included in genomic proﬁles offered online. We identiﬁed seven companies that offer predic-
tive genomic proﬁling. We searched PubMed for meta-analyses and HuGE reviews of studies of gene-disease associations published from
2000 through June 2007 in which the genotypes of people with a disease were compared with those of a healthy or general-population
control group. The seven companies tested at least 69 different polymorphisms in 56 genes. Of the 56 genes tested, 24 (43%) were not
reviewed in meta-analyses. For the remaining 32 genes, we found 260 meta-analyses that examined 160 unique polymorphism-disease
associations, of which only 60 (38%) were found to be statistically signiﬁcant. Even the 60 signiﬁcant associations, which involved 29
different polymorphisms and 28 different diseases, were generally modest, with synthetic odds ratios ranging from 0.54 to 0.88 for pro-
tective variants and from 1.04 to 3.2 for risk variants. Furthermore, genes in cardiogenomic proﬁles weremore frequently associated with
noncardiovascular diseases than with cardiovascular diseases, and though two of the ﬁve genes of the osteogenomic proﬁles did show
signiﬁcant associations with disease, the associations were not with bone diseases. There is insufﬁcient scientiﬁc evidence to conclude
that genomic proﬁles are useful in measuring genetic risk for common diseases or in developing personalized diet and lifestyle recom-
mendations for disease prevention.Introduction
Advances in genomics are expected to increase our under-
standing of the etiology and pathogenesis of common dis-
eases such as type 2 diabetes, cardiovascular disease, and
cancer. They are also expected to offer new opportunities
for the prevention, early detection, and treatment of these
diseases, in part by allowing health care providers to use
individualized preventive and therapeutic strategies based
on patients’ genomic proﬁles.1 So far, the complex interac-
tions between genetic and environmental causes of most
common diseases are poorly understood and the poten-
tial usefulness of genome-based interventions is unclear.
Nevertheless, several companies already offer personalized
lifestyle health recommendations and nutritional supple-
ments based on clients’ genomic proﬁles, and many others
are developing similar strategies (see Web Resources).2
Because most common diseases are caused by complex
interactions among multiple genetic and nongenetic fac-
tors, each of which confer only minor increases in risk,
the predictive value of genomic proﬁling may be insufﬁ-
cient as a useful basis for personalized nutritional and life-
style recommendations. When differences in disease risk
between high-risk and low-risk groups are small, we would
expect both groups to beneﬁt fairly equally from general
interventions unless the interventions are proven more
effective for individuals with certain genotypes; however,evidence of such gene-environment interactions is still
lacking. For these reasons, it has been argued that the use
of genomic proﬁles to devise personalized lifestyle recom-
mendations is premature and misleading.2–6
A pervasive problem of research on genetic associations
is that positive results are often difﬁcult to replicate.7,8
Results of individual gene-disease association studies have
a high probability of being false-positive, and therefore ad-
equate replications of the same gene-disease association in
independent-study populations are essential.7,9 Systematic
reviews and meta-analyses of epidemiologic studies on
genotype-disease associations are valuable approaches for
assessing the credibility of associations reported in single
studies.6,7,10 In this study, we assess the scientiﬁc evidence
for the usefulness of commercially available genomic pro-
ﬁles by reviewing meta-analyses of gene-disease associa-
tions for the genetic variants included in the proﬁles.
Material and Methods
Searching
Starting from the Genewatch 2006 report on individually tailored
nutrition recommendations based on genomic proﬁling,2 we
searched the Internet and identiﬁed seven companies that offer
predictive genetic testing using multiple markers (Genelex, Geno-
vations, Genosolutions, Integrative Genomics, Salugen, Sciona
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polymorphisms included in these proﬁles from the companies’
Web sites (see Web resources), from online sample reports, and
from a published article.11 The genes and polymorphisms in-
cluded in the proﬁles are listed in Table S1 (available online). Three
companies did not specify the polymorphisms that they tested.
We assumed that these companies tested the same polymor-
phisms in genes also tested by other companies; however, when
their proﬁles included a gene not tested by any other company,
we reviewed available literature on any polymorphism of the
gene. We searched PubMed for meta-analyses and Human Ge-
nome Epidemiology (HuGE) reviews published from 2000
through June 2007 regarding susceptibility to any disease associ-
ated with these polymorphisms.
Selection of Meta-Analyses
In conducting the PubMed literature search, we used both the ab-
breviation and the full name of each of the 56 genes tested by the
seven companies, in combination with the query term ‘‘meta-
analysis and (gene or polymorphism),’’ without specifying any
polymorphisms or diseases. Next, we hand-searched all retrieved
references for the exact polymorphism(s) studied, the study popu-
lation, and the disease examined.We considered alternative anno-
tations of polymorphisms and veriﬁed them in the OnlineMende-
lian Inheritance in Man (OMIM) database. We included only
meta-analyses published in English that compared the frequency
of a polymorphism among people with the disease in question
with the frequency among healthy or general-population con-
trols. We did not exclude studies because of statistically signiﬁcant
heterogeneity in the effect sizes of the individual studies. Formeta-
analyses in which there was signiﬁcant heterogeneity, we report
the meta-analysis with one or two outlying studies removed or
a subgroup analysis of three or more studies involving populations
of Western European descent (the most commonly studied sub-
group), if these had less or no signiﬁcant heterogeneity, depending
on the availability of information. If more than one meta-analysis
Figure 1. Flow Chart of Selection of
Meta-Analyses
examined the same polymorphism-dis-
ease association, we used the most com-
prehensive one.
Data Extraction
We retrieved data on the gene, the poly-
morphism, and the disease examined in
each study, as well as the number of case
and of control subjects involved; the
odds ratio and 95% conﬁdence interval
(CI) for the polymorphism-disease associa-
tion; and the heterogeneity in effect sizes
of the individual studies. Many of the
meta-analyses we examined presented
multiple odds ratios for the same polymor-
phism-disease association by considering
different genetic models (e.g., dominant
effect of risk alleles, recessive effect, or
per allele effect). We used the per-allele
odds ratio if all models yielded the same
conclusion about the presence of associa-
tion. If the per-allele odds ratio was not statistically signiﬁcant,
we selected the model (dominant or recessive effect of risk allele)
with the highest odds ratio, assuming that the companies were
referring to that speciﬁc association. If random and ﬁxed effects
models were presented, we obtained the odds ratios from the
random-effects models.
Results
The seven companies tested at least 69 different polymor-
phisms in 56 genes (Table S1). Only one gene (MTHFR
[MIM 07093]) was tested by all seven companies, seven
genes (CETP [MIM 118470], COL1A1 [MIM 120150],
GSTM1 [MIM 138350], GSTP1 [MIM 134660], IL-6 [MIM
147620], TNF-a [MIM 191160], and VDR [MIM 601769])
were tested by ﬁve or six companies, and 19 genes (34%)
were tested by only one company.
We identiﬁed 260 meta-analyses that met our criteria;
they addressed 46 of the 69 polymorphisms and 32
(57%) of the 56 genes tested by the seven companies
(Figure 1 and Table S1), as well as 160 unique associations
between a genetic polymorphism and a disease. Sixteen
meta-analyses (10%) addressed the two polymorphisms
in the MTHFR gene (C677T and A1298C), 13 addressed
polymorphisms in TNF-a, 12 addressed polymorphisms
in GSTM1, 11 addressed polymorphisms in GSTP1 and
GSTT1, and ten addressed polymorphisms in VDR.
Of the 160 unique polymorphism-disease associations
that had been examined by meta-analysis, 60 were statisti-
cally signiﬁcant (Figure 1 and Table S2), including signiﬁ-
cant associations for 29 of 69 polymorphisms in 25
(45%) of the 56 genes. However, statistically signiﬁcant
associations were generally modest, with signiﬁcant odds
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ratios (ORs) ranging from 0.54 to 0.88 for protective alleles
or genotypes and from 1.04 to 1.50 for risk alleles or geno-
types, except for the risk for systemic lupus erythematosus
associated with TNF-a (OR 2.1, 95%CI 1.6-2.7) and the risk
for Alzheimer’s disease associated with APOE-4 (OR 3.2,
95% CI 2.7-3.8; [MIM 107740]). Polymorphisms were asso-
ciated with signiﬁcantly increased or decreased risk for 28
different diseases. The MTHFR C677T polymorphism was
signiﬁcantly associated with risk for seven different dis-
eases, GSTT1 [MIM 600436] with risk for six, TNF-a with
risk for ﬁve, and GSTM1 and MTHFR A1298C with risk
for four. Twelve meta-analyses showed signiﬁcant associa-
tions between polymorphisms and risk for cardiovascular
disease (including myocardial infarction, coronary steno-
sis, coronary artery disease, and coronary heart disease),
ﬁve between polymorphisms and stroke, and four between
polymorphisms and Alzheimer’s disease or acute leukemia.
On average, meta-analyses showed a signiﬁcant associa-
tion with disease risk for 58% of the genes included in each
proﬁle (range 38%–83%) (Table 1). These signiﬁcant associ-
ations, however, were often with risk for disease outcomes
other than those associated with the ‘‘proﬁle’’ (Table 1). For
example, statistically signiﬁcant associations with disease
risk were found for only two of the ﬁve genes included in
osteogenomic proﬁles, and these associations were with
risk for Alzheimer’s disease, asthma, non-Hodgkin’s lym-
phoma, obesity, and systemic lupus erythematosus, rather
than with risk for bone disorders.
Discussion
Although companies offering genomic proﬁles did not
specify how they selected polymorphisms for inclusion
in the proﬁles, they probably did so on the basis of statisti-
cally signiﬁcant results from association studies. Because
positive results from single gene-disease association studies
are often not replicated in subsequent studies,12 one study
showing a statistically signiﬁcant association is considered
insufﬁcient evidence of genetic association.10 Our review
of meta-analyses found signiﬁcant associations with dis-
ease risk for fewer than half of the 56 genes that are tested
in commercially available genomic proﬁles. Various poly-
morphisms of these genes were associated with risk for
28 different disorders. Many of these disorders were unre-
lated to the ostensible target condition, and the associa-
tions were generally modest.
Before interpreting our results, we need to clarify four
issues regarding the review strategy we used. First, our
paper addressed predictive genomic proﬁles that are sold
online and that aim to personalize nutrition and other
lifestyle health recommendations. The review did not as-
sess the scientiﬁc basis of gene-expression proﬁles and
pharmacogenomic applications. Although there may be
applications that have stronger scientiﬁc support than
others, there are clearly promising developments in this
area.13,14 Second, the information on genes and polymor-The Aphisms in this study was obtained from company web-
sites and online sample reports. As of November 2007,
all seven companies were still selling the proﬁles, but
two no longer speciﬁed on their Web sites which genes
they were actually testing. Although these companies
may now use other polymorphisms to proﬁle the disease
risk of their clients, the scientiﬁc evidence for the disease
risk associated with these other polymorphisms is likely to
be similar to that for the polymorphisms we reviewed.
Third, we limited our search for meta-analyses to those
on the association between polymorphisms and disease
susceptibility, and we excluded those on associations
with intermediate, quantitative phenotypes or risk factors
such as blood pressure or bone mass density because the
need for preventive intervention varies with the level of
these traits. We did include meta-analyses of associations
between polymorphisms and risk for conditions deﬁned
by clinically relevant thresholds, such as hypertension
or osteoporotic fractures. Because the genetic proﬁles of
the companies are offered to the general public, we re-
stricted our search to meta-analyses of studies that in-
cluded healthy or general-population controls. Because
the predictive value of genetic testing depends on disease
risk, genotype frequencies, and odds ratios for the associ-
ation between disease risk and polymorphisms in a par-
ticular genetic proﬁle, all of which may differ between
populations, the proﬁles should be evaluated in the target
population.15 This explains why genetic testing for APOE,
Factor II [MIM 176930], and Factor V [MIM 227400] can
have lower predictive value in a general population con-
text but be very informative to persons with a family his-
tory. Fourth, we did not exclude meta-analyses on the ba-
sis of quality criteria, even though there were obvious
differences in quality among meta-analyses. The authors
of larger meta-analyses often selected studies according
to a set of strict criteria, whereas the authors of smaller
ones often combined all available studies. In addition,
more than a quarter of the meta-analyses in Table S2 re-
ported statistically signiﬁcant heterogeneity in effect sizes
among studies. Several of the meta-analyses that found
a signiﬁcant association involving heterogeneous study
populations did not ﬁnd a signiﬁcant association when
the analyses were restricted to a subgroup of more homog-
enous studies.16,17 Application of strict quality criteria
would have reduced the number of meta-analyses in the
present review substantially.
These methodological choices partly explain why we
found no meta-analyses for 24 of the 56 genes. There
were meta-analyses available for many of these genes,
but these meta-analyses could not evidence the utility of
genomic proﬁling in the general population. For example,
we found several meta-analyses of pharmacogenomic stud-
ies (e.g., for CYP2C9 [MIM 601130] and CYP2C19 [MIM
124020]18,19), several meta-analyses on diseases that do
not affect the average individual in the general population
(such as IL-10 [MIM 124092] and recurrent pregnancy
loss20), and meta-analyses on health traits (e.g., smokingmerican Journal of Human Genetics 82, 593–599, March 2008 595
Table 1. Overview of Meta-Analyses of Gene-Disease Association Studies by Genomic Profile
Company Genomic Profile Polymorphismsa
Genes Meta-Analyses
Diseases Associated with Polymorphisms
in the Meta-AnalysesTotal
Significant
Association
with Disease Totalb
Significant
Association
with Disease
1 Heart health 15 13 5 43 21 Acute leukemia, Alzheimer’s disease, asthma,
colorectal cancer, coronary artery disease,
coronary heart disease, depression, gastric
cancer, IgA nephropathy, non-Hodgkin’s
lymphoma, obesity, psoriasis, schizophrenia,
systemic lupus erythematosus (SLE), stroke,
venous thrombosis
Bone health 7 4 2 28 6 Alzheimer’s disease, asthma, non-Hodgkin’s
lymphoma, obesity, psoriasis, SLE
Insulin resistance 6 5 4 32 10 Acute leukemia, Alzheimer’s disease, asthma,
bladder cancer, breast cancer, colorectal
cancer, head and neck cancer, non-Hodgkin’s
lymphoma, obesity, psoriasis, Parkinson’s
disease, SLE
Inflammation
health
7 6 5 48 17 Acute leukemia, bladder cancer, head and
neck cancer, breast cancer, colorectal cancer,
Parkinson’s disease, Alzheimer’s disease,
asthma, non-Hodgkin’s lymphoma, obesity,
psoriasis, SLE
Antioxidant/
detoxification
8 6 4 31 12 Acute leukemia, bladder cancer, breast
cancer, colorectal cancer, coronary heart
disease, head and neck cancer, Parkinson’s
disease
2c OsteoGenomic 5 5 2 22 6 Alzheimer’s disease, asthma, non-Hodgkin’s
lymphoma, obesity, psoriasis, SLE
ImmunoGenomic R4 4 2 17 6 Asthma, non-Hodgkin’s lymphoma, obesity,
psoriasis, schizophrenia, SLE
CardioGenomic 13 10 6 30 18 Acute leukemia, age-related macular
degeneration, Alzheimer’s disease, colorectal
cancer, coronary heart disease, coronary
stenosis, hypertension, myocardial
infarction, schizophrenia, stroke
DetoxiGenomic R19 16 6 62 15 Acute leukemia, bladder cancer, breast
cancer, colorectal cancer, endometriosis,
esophageal cancer, head and neck cancer,
obsessive compulsive disorder, Parkinson’s
disease
3 Cardiogenomic R13 12 7 39 26 Acute leukemia, Alzheimer’s disease, age-
related macular degeneration, colorectal
cancer, coronary artery disease, coronary
heart disease, coronary stenosis, depression,
gastric cancer, hypertension, myocardial
infarction, schizophrenia, stroke, venous
thrombosis
Estrogenomic R14 13 9 73 32 Acute leukemia, Alzheimer’s disease, asthma,
age-related macular degeneration, colorectal
cancer, coronary artery disease, coronary
heart disease, coronary stenosis, depression,
endometriosis, esophageal cancer, gastric
cancer, myocardial infarction, non-Hodgkin’s
lymphoma, obesity, obsessive compulsive
disorder, psoriasis, schizophrenia, SLE,
stroke, venous thrombosis
Immunogenomic R5 5 2 19 6 Asthma, non-Hodgkin’s lymphoma, obesity,
psoriasis, SLE, schizophrenia
Neurogenomic R6 5 4 46 17 Acute leukemia, Alzheimer’s disease, bladder
cancer, colorectal cancer, coronary artery
disease, depression, gastric cancer, head and
neck cancer, obsessive compulsive disorder,
schizophrenia, stroke, venous thrombosis
596 The American Journal of Human Genetics 82, 593–599, March 2008
Table 1. Continued
Company Genomic Profile Polymorphismsa
Genes Meta-Analyses
Diseases Associated with Polymorphisms
in the Meta-AnalysesTotal
Significant
Association
with Disease Totalb
Significant
Association
with Disease
Osteogenomic R5 5 2 22 6 Alzheimer disease, asthma, non-Hodgkin’s
lymphoma, obesity, psoriasis, SLE
Inflammation R6 5 4 37 18 Acute leukemia, Alzheimer’s disease, asthma,
colorectal cancer, coronary artery disease,
depression, gastric cancer, hypertension,
non-Hodgkin’s lymphoma, obesity, psoriasis,
schizophrenia, SLE, stroke, venous
thrombosis
4 Enhanced Basic
Screening Panel
R12 12 5 52 21 Acute leukemia, Alzheimer’s disease, asthma,
colorectal cancer, coronary artery disease,
depression, gastric cancer, hypertension,
myocardial infarction, non-Hodgkin’s
lymphoma, obesity, Parkinson’s disease,
schizophrenia, SLE, stroke, venous
thrombosis
5 GenoScore R5 5 4 15 10 Acute leukemia, alcoholism, anorexia
nervosa, Alzheimer’s disease, colorectal
cancer, schizophrenia, type 2 diabetes
6 Nutritional
Genetic
Profile
24 19 9 87 33 Acute leukemia, Alzheimer’s disease, asthma,
bladder cancer, breast cancer, colorectal
cancer, coronary artery disease, coronary
heart disease, depression, gastric cancer,
head and neck cancer, IgA nephropathy,
non-Hodgkin’s lymphoma, obesity,
Parkinson’s disease, schizophrenia, SLE,
stroke, type 2 diabetes, venous thrombosis
7d Personal DNA
Analysis Starter
Kit
19 19 9 91 33 Acute leukemia, Alzheimer’s disease, asthma,
bladder cancer, breast cancer, colorectal
cancer, coronary heart disease, gastric
cancer, head and neck cancer, IgA
nephropathy, Parkinson’s disease, coronary
artery disease, depression, schizophrenia,
stroke, venous thrombosis, type 2 diabetes,
non-Hodgkin’s lymphoma, obesity, SLE
a When companies did not specify exact polymorphisms, the number indicates the number of specified polymorphisms plus the number of genes for which
polymorphisms were not specified, indicating that they test at least one polymorphism in these genes.
b Refers to total number of unique meta-analyses (see Figure 1).
c This company now also offers neurogenomic and estrogenomic profiles, but no specific information was available for these profiles.
d This company did not specify polymorphisms, but it only tests genes that are also considered by other companies. Hence, we assumed that this company
also tests the same polymorphisms as do the other companies.behavior and CYP2A6 [122720]21). Furthermore, for many
genes we found meta-analyses on other polymorphisms
(e.g., IL-10 G[1082]A22 and LPL Asn291Ser23) or on re-
lated genes (e.g., Leptin Receptor gene (LEPR; [MIM
601007]), but not for Leptin [MIM 164160]).24
This review shows that the excess disease risk associated
with many genetic variants included in genomic proﬁles
has not been investigated in meta-analyses or has been
found to be minimal or not signiﬁcant. These results raise
concern about the validity of combining tests for many
different genetic variants into proﬁles, especially when
the companies offering them do not describe how they
create a composite proﬁle from the results of tests for sin-
gle genetic markers. One company reports that they use
complex mathematical algorithms to produce personal-Theized diet and lifestyle recommendations. Another recom-
mends basic nutritional or lifestyle-change support for
homozygous negatives, added support for heterozygous
positives, and maximum support for homozygous posi-
tives, which suggests that they are using single genetic
markers as the basis for their recommendations. This reli-
ance on single genetic markers is particularly worrisome
given the limited predictive value of results from testing
single susceptibility genes with small effects.25–27 To be
meaningful, a genetic risk proﬁle should combine infor-
mation about the disease risk associated with multiple
genes, and creating such a proﬁle would require extensive
knowledge of gene-gene interactions, which are even less
well understood than the disease risk associated with indi-
vidual polymorphisms.American Journal of Human Genetics 82, 593–599, March 2008 597
How the companies we examined use their clients’ ge-
netic proﬁles to tailor individualized nutrition-supplement
and lifestyle recommendations is another intriguing puz-
zle. Evidence on gene-diet interactions is still preliminary
because trials designed to test these interactions have
thus far yielded mainly inconclusive results.28 Further-
more, several genes, such as ACE [MIM 106180], APOE,
and MTHFR, increase people’s risk for some diseases and
decrease their risk for others (Table S2). For example,
MTHFR 677TT was associated with an increased risk for
depression, stroke, coronary artery disease, gastric cancer,
schizophrenia, and venous thrombosis, but it was associ-
ated with a decreased risk for colorectal cancer. Hence,
the putative health effects of preventive interventions tai-
lored to a person’s MTHFR genotype may not be entirely
beneﬁcial. Finally, when proﬁles are composed of low-
risk susceptibility genes, people with purportedly ‘‘high-
risk’’ proﬁles may be at only slightly higher risk of disease
than are people with ‘‘low-risk’’ proﬁles. One possible dan-
ger of marketing lifestyle recommendations to people with
‘‘high-risk’’ proﬁles is that those with ‘‘low-risk’’ proﬁles
could be led to mistakenly believe that they have little
need to make healthy lifestyle changes. The predictive
value of genomic proﬁling may simply be insufﬁcient for
targeting interventions when low-risk groups will receive
no intervention at all.29 It also needs to be investigated
whether genomic proﬁling can usefully identify the better
from the worse responders in the choice between two treat-
ments.
Although genomic proﬁling may have potential to
enhance the effectiveness and efﬁciency of preventive in-
terventions, to date the scientiﬁc evidence for most associ-
ations between genetic variants and disease risk is insufﬁ-
cient to support useful applications. Despite advances in
nutrigenomics and pharmacogenomics research,30 it could
take years, if not decades, before lifestyle and medical in-
terventions can be responsibly and effectively tailored to
individual genomic proﬁles.
Supplemental Data
Two tables can be found with this paper online at http://www.
ajhg.org/.
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